Future Outlook on FDA Rulemaking for Continuously Learning AI Medical Software Introduction to AI ML SaMD and Regulatory Landscape As the healthcare landscape evolves with digital technologies, the integration of artificial intelligence (AI) and machine learning (ML) in software as a medical device (SaMD) has become increasingly relevant. The U.S. Food and Drug Administration (FDA) recognizes the potential of AI ML SaMD to enhance clinical outcomes while also presenting unique regulatory challenges. This article aims to provide a comprehensive overview of the future outlook on FDA rulemaking concerning continuously learning AI medical software, focusing on essential concepts like algorithm change…

Global convergence on AI change plans across FDA, EMA and other regulators Global Convergence on AI Change Plans Across FDA, EMA and Other Regulators The introduction of artificial intelligence (AI) and machine learning (ML) technologies into Software as a Medical Device (SaMD) has prompted a significant shift in regulatory frameworks. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are actively working to establish coherent guidelines for the oversight of AI ML SaMD algorithm change control and predetermined change plans. This article serves as a comprehensive guide for digital health, regulatory, clinical, and quality leaders involved…

Aligning Software Configuration Management with AI Model Lifecycle The digital health landscape is increasingly dominated by software as a medical device (SaMD), particularly solutions that leverage artificial intelligence (AI) and machine learning (ML). As these technologies evolve, ensuring regulatory compliance while maintaining effective software configuration management is paramount. This guide provides a comprehensive overview of aligning your software configuration management practices with the AI model lifecycle, specifically focusing on AI ML SaMD algorithm change control and predetermined change plans. Understanding the Regulatory Framework for AI ML SaMD The US Food and Drug Administration (FDA) has laid a regulatory framework for…

Template structure for FDA submission of a SaMD algorithm change plan Template Structure for FDA Submission of a SaMD Algorithm Change Plan The regulation of Software as a Medical Device (SaMD) has evolved significantly with the growing inclusion of artificial intelligence (AI) and machine learning (ML) technologies. Understanding how to submit a SaMD algorithm change plan to the U.S. Food and Drug Administration (FDA) is crucial for developers and regulatory professionals navigating this complex landscape. This article will provide a step-by-step tutorial to help you structure your submission effectively. Understanding FDA Guidance on SaMD Before delving into the specifics of…

Regulatory differences between locked and adaptive AI models in SaMD Understanding Regulatory Differences Between Locked and Adaptive AI Models in SaMD The integration of artificial intelligence (AI) and machine learning (ML) into software as a medical device (SaMD) presents unique regulatory challenges. Regulatory bodies, including the U.S. Food and Drug Administration (FDA), have established frameworks that need to be understood by digital health, regulatory, clinical, and quality leaders. This article serves as a comprehensive guide on the regulatory differences between locked and adaptive AI models in SaMD, focusing on algorithm change control and predetermined change plans. By outlining the required…